Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | ABL1 | P00519 | 3/20 | 0.59 |
| ▸ | BCR | P11274 | 3/20 | 0.59 |
| ▸ | NQO2 | P16083 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | AHR | P35869 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.50 |
| ▸ | TUBB | P07437 | 2/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919069 | 1.00 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP1A2ABL1BCR | |
| SCHEMBL6449307 | 0.87 | TUBB1 (0.63) | CYP1A1CYP1B1CYP1A2ABL1BCR | |
| SCHEMBL918728 | 0.87 | TUBB1 (0.63) | CYP1A1CYP1B1CYP1A2ABL1BCR | |
| SCHEMBL8009626 | 0.83 | CYP1A2 (0.44) | CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL6453162 | 0.81 | TUBB1 (0.62) | CYP1A1CYP1B1CYP1A2ALOX5CYP3A4 | |
| SCHEMBL918107 | 0.81 | PTGS1 (0.44) | CYP1A1CYP1B1CYP1A2NQO2ALOX5 | |
| SCHEMBL917865 | 0.81 | TUBB1 (0.62) | CYP1A1CYP1B1CYP1A2ALOX5CYP3A4 | |
| SCHEMBL6448424 | 0.79 | TUBB1 (0.41) | CYP1A1CYP1B1CYP1A2ABL1BCR | |
| SCHEMBL917832 | 0.79 | TUBB1 (0.41) | CYP1A1CYP1B1CYP1A2ABL1BCR | |
| SCHEMBL918373 | 0.79 | NFE2L2 (0.61) | NQO2ABCB1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | CYP1A1 3243/4885CYP1B1 2183/4885CYP1A2 3272/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | CYP1A1 2632/4885CYP1B1 1910/4885CYP1A2 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.